1
|
Thiem A, Mashhadiakbar P, Cussigh C, Hassel JC, Grimmelmann I, Gutzmer R, Schlaak M, Heppt MV, Dücker P, Hüning S, Schulmeyer L, Schilling B, Haferkamp S, Ziemer M, Moritz RKC, Hagelstein V, Terheyden P, Posch C, Gaiser MR, Kropp P, Emmert S, Müller B, Tietze JK. Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicenter study. J Eur Acad Dermatol Venereol 2022; 37:884-893. [PMID: 36433671 DOI: 10.1111/jdv.18778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Accepted: 11/08/2022] [Indexed: 11/27/2022]
Abstract
BACKGROUND Choosing the adequate systemic treatment for melanoma is driven by clinical parameters and personal preferences. OBJECTIVE Evaluation of the impact of disease and treatment on the daily life of patients receiving systemic therapy for melanoma. METHODS A German-wide, cross-sectional comparative study was conducted at 13 specialized skin cancer centres from 08/2020 to 03/2021. A questionnaire was distributed to assess patients' perception of disease and symptoms, the impact of their current treatment on quality of life (QOL) and activities, adverse events (AEs), therapeutic visits, as well as believe in and satisfaction with their current systemic melanoma treatment. Patient-reported outcomes (PROs) were rated on a continuous numerical rating scale or selected from a given list. RESULTS Four hundred and fourteen patients with systemic melanoma therapy were included. 359 (87%) received immune checkpoint inhibition (ICI) and 55 (13%) targeted therapy (TT). About 1/3 of patients were adjuvantly treated, the remaining because of unresectable/metastatic melanoma. In subgroup analyses, only in the adjuvant setting, TT patients reported a significant decrease in their treatment associated QOL compared to patients with ICI (p = 0.02). Patients with TT were 1.9 times more likely to report AEs than patients with ICI, a difference being significant just for the adjuvant setting (p = 0.01). ICI treatment intervals differed significantly between adjuvant and unresectable/metastatic setting (p = 0.04), though all patients, regardless of their specific ICI drug, evaluated their treatment frequency as adequate. TT patients with dabrafenib/trametinib (n = 37) or encorafenib/binimetinib (n = 15) did not differ regarding the strain of daily pill intake. Patients older than 63 years rated various PROs better than younger patients. CONCLUSIONS Patients evaluated their treatment mainly positively. ICI might be preferred over TT regarding QOL and patient-reported AEs in the adjuvant setting. Older melanoma patients appeared to be less impacted by their disease and more satisfied with their treatment.
Collapse
Affiliation(s)
- A. Thiem
- Clinic and Policlinic for Dermatology and Venereology University Medical Center Rostock Rostock Germany
| | - P. Mashhadiakbar
- Clinic and Policlinic for Dermatology and Venereology University Medical Center Rostock Rostock Germany
| | - C. Cussigh
- Department of Dermatology and National Center for Tumor Diseases (NCT) Heidelberg University Hospital Heidelberg Germany
| | - J. C. Hassel
- Department of Dermatology and National Center for Tumor Diseases (NCT) Heidelberg University Hospital Heidelberg Germany
| | - I. Grimmelmann
- Skin Cancer Center Hannover, Department of Dermatology Hannover Medical School Hannover Germany
| | - R. Gutzmer
- Skin Cancer Center Hannover, Department of Dermatology Hannover Medical School Hannover Germany
- Skin Cancer Center Minden, Department of Dermatology, Johannes‐Wesling‐Klinikum Minden/Ruhr‐University, Bochum Minden Germany
| | - M. Schlaak
- Department of Dermatology and Allergy University Hospital of Munich (LMU) Munich Germany
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin, Department of Dermatology, Venereology and Allergology Berlin Germany
| | - M. V. Heppt
- Department of Dermatology and Comprehensive Cancer Center Erlangen‐European Metropolitan Area of Nuremberg (CCC ER‐EMN), Universitätsklinikum Erlangen, Friedrich‐Alexander‐University Erlangen‐Nürnberg Erlangen Germany
| | - P. Dücker
- Department of Dermatology, Hospital of Dortmund Dortmund Germany
| | - S. Hüning
- Department of Dermatology, Hospital of Dortmund Dortmund Germany
| | - L. Schulmeyer
- Department of Dermatology, Venereology and Allergology University Hospital Würzburg Würzburg Germany
| | - B. Schilling
- Department of Dermatology, Venereology and Allergology University Hospital Würzburg Würzburg Germany
| | - S. Haferkamp
- Department of Dermatology University Hospital Regensburg Regensburg Germany
| | - M. Ziemer
- Department of Dermatology, Venereology and Allergology University Medical Center Leipzig Leipzig Germany
| | - R. K. C. Moritz
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin, Department of Dermatology, Venereology and Allergology Berlin Germany
- Department of Dermatology and Venereology, Martin‐Luther‐University Halle‐Wittenberg Halle (Saale) Germany
| | - V. Hagelstein
- Department of Dermatology, Allergology, and Venereology University of Lübeck Germany
| | - P. Terheyden
- Department of Dermatology, Allergology, and Venereology University of Lübeck Germany
| | - C. Posch
- Department of Dermatology, Venereology and Allergology, Clinic Hietzing Vienna Healthcare Group Vienna Austria
- Department of Dermatology and Allergy, School of Medicine, German Cancer Consortium (DKTK) Technical University of Munich Munich Germany
- Faculty of Medicine Sigmund Freud University Vienna Vienna Austria
| | - M. R. Gaiser
- Department of Dermatology, Venerology and Allergology, Medical Faculty Mannheim, University Medical Center Mannheim Heidelberg University Mannheim Germany
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg Germany
| | - P. Kropp
- Institute of Medical Psychology and Medical Sociology University Medical Center Rostock Rostock Germany
| | - S. Emmert
- Clinic and Policlinic for Dermatology and Venereology University Medical Center Rostock Rostock Germany
| | - B. Müller
- Institute of Medical Psychology and Medical Sociology University Medical Center Rostock Rostock Germany
| | - J. K. Tietze
- Clinic and Policlinic for Dermatology and Venereology University Medical Center Rostock Rostock Germany
| |
Collapse
|
2
|
Gutzmer R, Eigentler T, Mohr P, Weichenthal M, Dücker P, Gebhardt C, Göppner D, Grimmelmann I, Haferkamp S, Kähler K, Meier F, Pföhler C, Sickmann T, Sindrilaru A, Terheyden P, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Schadendorf D. 1079P Comparison of effectiveness and safety of nivolumab monotherapy or in combination therapy with ipilimumab in therapy-naïve and pretreated patients with advanced melanoma within the German noninterventional study NICO. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
3
|
Dücker P, Brehmer A, Nashan D. Cemiplimab in der Anwendung bei hochbetagten Patienten. Aktuelle Dermatologie 2021. [DOI: 10.1055/a-1396-8087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
ZusammenfassungWir berichten über den erfolgreichen Einsatz von Cemiplimab bei insgesamt 23 hochbetagten Patienten mit fortgeschrittenen und/oder metastasierten Plattenepithelkarzinomen, die bei guter Verträglichkeit trotz Komorbiditäten nephrogener oder kardialer Genese, Diabetes und auch bei Vorliegen von Zweitmalignomen ein gutes Ansprechen boten. Eine komplette Remission konnte bei 10 Patienten, eine partielle Remission bei 8 Patienten erreicht werden. 6 der 7 Patienten mit Zweittumoren zeigten ein Ansprechen. Ein Ansprechen zeichnete sich meist schon nach wenigen Therapiezyklen ab.
Collapse
Affiliation(s)
- P. Dücker
- Klinik für Dermatologie, Klinikum Mitte Dortmund
| | - A. Brehmer
- Klinik für Dermatologie, Klinikum Mitte Dortmund
| | - D. Nashan
- Klinik für Dermatologie, Klinikum Mitte Dortmund
| |
Collapse
|
4
|
Gutzmer R, Eigentler T, Mohr P, Weichenthal M, Dücker P, Gebhardt C, Göppner D, Haferkamp S, Kähler K, Meier F, Pföhler C, Satzger I, Sickmann T, Sindrilaru A, Terheyden P, Ugurel S, Ulrich J, Utikal J, Weishaupt C, Schadendorf D. 1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
5
|
Dücker P, Hüning S, Rohde S, Lorenzen J, Nashan D. [Merkel cell carcinoma in chronic lymphocytic leukemia : Successful treatment with PD-L 1 inhibition, avelumab and chlorambucil]. Hautarzt 2020; 71:553-556. [PMID: 32394077 DOI: 10.1007/s00105-020-04599-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
We report the case of an 85-year-old chronic lymphocytic leukemia patient with a local metastatic MCVPyV-negative Merkel cell carcinoma at initial diagnosis. Therapy comprised surgical excision and radiotherapy but without lymphadenectomy. Six months after the primary diagnosis, liver metastases were detected. They responded to the PD-L1 inhibitor avelumab for more than 15 months. Thus, we postulate a synergistic effect of combined therapy with chlorambucil and avelumab through a mutual improvement of immune function, from which both diseases benefit.
Collapse
Affiliation(s)
- P Dücker
- Klinik für Dermatologie, Klinikum Dortmund, Beurhausstr. 40, 44137, Dortmund, Deutschland.
| | - S Hüning
- Klinik für Dermatologie, Klinikum Dortmund, Beurhausstr. 40, 44137, Dortmund, Deutschland
| | - S Rohde
- Institut für Radiologie und Neuroradiologie, Klinikum Dortmund, 44137, Dortmund, Deutschland
| | - J Lorenzen
- Pathologisches Institut, Klinikum Dortmund, 44137, Dortmund, Deutschland
| | - D Nashan
- Klinik für Dermatologie, Klinikum Dortmund, Beurhausstr. 40, 44137, Dortmund, Deutschland
| |
Collapse
|
6
|
Hüning S, Malek M, Reuter T, Uszynska-Jast M, Dücker P. Lymphangioleiomyomatose als Differenzialdiagnose zum metastasierten malignen Melanom. Akt Dermatol 2016. [DOI: 10.1055/s-0042-109583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- S. Hüning
- Klinik für Dermatologie und Allergologie, Klinikum Dortmund gGmbH
| | - M. Malek
- Klinik für Dermatologie und Allergologie, Klinikum Dortmund gGmbH
| | | | | | - P. Dücker
- Klinik für Dermatologie und Allergologie, Klinikum Dortmund gGmbH
| |
Collapse
|
7
|
Reich-Schupke S, Alm J, Altmeyer P, Bachter D, Bayerl C, Beissert S, Bieber T, Böhmer J, Dill D, Dippel E, Dücker P, Effendy I, El Gammal S, Elsner P, Enk A, Feldmann-Böddeker I, Frank H, Gehring W, Gieler U, Goebeler M, Görge T, Gollnick H, Grabbe S, Gross G, Gudat W, Happ A, Herbst R, Hermes B, Hoff NP, John SM, Jungelhülsing M, Jünger M, Kaatz M, Kapp A, Kaufmann R, Klode J, Knaber K, König A, Krieg T, Kohl P, Kowalzick L, Lehmann P, Löffler H, Maschke J, Marsch W, Mechtel D, Mohr P, Moll I, Müller M, Nashan D, Ockenfels HM, Peter RU, Pillekamp H, Rompel R, Ruzicka T, Salfeld K, Sander C, Schaller J, Scharffetter-Kochanek K, Schuler G, Schulze HJ, Schwarz T, Splieth B, Stege H, Stolz W, Strölin A, Tran H, Tronnier M, Ulrich J, Vogt T, Wagner G, Welzel J, Willgeroth T, Wollina U, Zillikens D, Zouboulis CC, Zuberbier T, Zutt M, Stücker M. [Phlebology in German departments of dermatology. An analysis on behalf of the German Society of Phlebology]. Hautarzt 2013; 64:685-94. [PMID: 24022632 DOI: 10.1007/s00105-013-2623-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND Phlebologic diseases have become extremely common and have major socio-economic impact. However, the percentage of dermatologists working in phlebology appears to be decreasing according to the data of the German Society of Phlebology (DGP). METHODS To investigate the reasons for this development, we--on behalf of the DGP--sent a questionnaire to 120 German Departments of Dermatology in autumn 2012. RESULTS In 76 returned questionnaires, the number of physicians with additional fellowship training in phlebology averaged 1.5; the average number of those who fulfill the criteria for training fellows in phlebology was 0.9. In 71.1 % of the departments there was a phlebologist. A special phlebologic outpatient clinic existed in 73.7 % of the departments. Sonography with Doppler (89.5 %) and duplex (86.8 %) was used as the most frequent diagnostic tool. For therapy, compression (94.7 %), sclerotherapy (liquid 78.9 %, foam 63.2 %, catheter 18.4 %), endoluminal thermic procedures (radio wave 28.9 %, laser 17.1 %) and surgery (especially crossectomy and stripping 67.1 %, phlebectomy of tributaries 75 %) were used. The average number of treatments was very heterogenous in the different departments. CONCLUSIONS Phlebology definitely plays an important role in dermatology. Most departments fulfill the formal criteria for the license to conduct advanced training in phlebology. A wide spectrum of phlebological diagnostic and therapeutic procedures is available.
Collapse
Affiliation(s)
- S Reich-Schupke
- Klinik für Dermatologie, Venerologie und Allergologie, Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken, Ruhr-Universität Bochum, Hiltroper Landwehr 11-13, 44805, Bochum, Deutschland,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Dücker P, Pfeiff B. [Two cases of side effects of a fumaric acid ester--local therapy]. Z Hautkr 1990; 65:734-6. [PMID: 2149475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
We report on two cases of adverse reactions to topical treatment with monoethyl fumarate. One patient suffering from atopic dermatitis reacted with contact dermatitis; the other, suffering from psoriasis, developed a generalized, partly pustulous exanthema as well as signs of systemic involvement, such as tachycardia and dyspnea. As the causative mechanism we suggest non-immunological contact urticaria syndrome.
Collapse
Affiliation(s)
- P Dücker
- Krankenhäuser des Märkischen Kreises, Dermat. Abtlg., Lüdenscheid
| | | |
Collapse
|
9
|
Dücker P, Pfeiff B, Pullmann H. [Malignant melanoma in café-au-lait spot]. Z Hautkr 1990; 65:751-3. [PMID: 2284835] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A 17-year-old female patient developed a superficially spreading malignant melanoma (level III, thickness 0.91 mm) on a typical café-au-lait spot. There were no metastases, as yet. On the basis of this unusual case, we discuss the incidence of development of malignant melanoma on melanotic spots.
Collapse
Affiliation(s)
- P Dücker
- Kreiskrankenhaus Lüdenscheid, Abteilung für Dermatologie
| | | | | |
Collapse
|